# Prevalence of Pseudotumor in Asymptomatic Patients After Metal-on-Metal Hip Arthroplasty

Daniel H. Williams, MBBCh, MSc, Nelson V. Greidanus, MD, MPH, Bassam A. Masri, MD, Clive P. Duncan, MD, MSc, and Donald S. Garbuz, MD, MHSc

Investigation performed at the Department of Orthopaedics, University of British Columbia, and Vancouver General Hospital, Vancouver, British Columbia, Canada

**Background:** The cause of recently reported pseudotumor formation in patients with metal-on-metal hip replacements is unknown. It has been postulated that there is an association between elevated levels of serum metal ions and pseudotumor formation. The primary purpose of this study was to assess the prevalence of pseudotumor formation in asymptomatic patients with a metal-on-metal total hip replacement after a minimum duration of follow-up of two years. A secondary purpose was to assess whether a correlation exists between elevated serum metal ion levels and pseudotumor formation.

**Methods:** In the present study, the prevalence of pseudotumor formation, as detected with ultrasound, was evaluated for thirty-one asymptomatic patients with a metal-on-metal total hip arthroplasty, twenty-four asymptomatic patients with a metal-on-metal total hip arthroplasty, twenty-four asymptomatic patients with a metal-on-metal hip resurfacing arthroplasty. Serum levels of cobalt and chromium were measured in the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups.

**Results:** Ten patients (32%) in the metal-on-metal total hip arthroplasty group had a solid or cystic mass, with another three patients (10%) having a substantial fluid collection. Five patients (25%) in the hip resurfacing arthroplasty group had a solid or cystic mass, with another patient (5%) having a fluid collection. Pseudotumor formation was significantly more frequent in the metal-on-metal total hip arthroplasty group compared with the metal-on-polyethylene total hip arthroplasty group (p = 0.015). We did not detect a significant correlation between the serum metal ion levels and the size of pseudotumor abnormality. The median serum metal ion level was greater in patients with pseudotumor formation than it was in those without pseudotumor formation, but the difference was not significant.

**Conclusions:** We recommend high-resolution ultrasound surveillance of all asymptomatic patients with a metal-on-metal implant that is known to result in high serum metal ion levels. Once a metal-on-metal implant is known to be associated with high serum metal ions, the measurement of ion levels does not helpfully contribute to surveillance.

Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

The rate of failure of total hip replacement in younger, more active patients under the age of forty years has been reported to be 21% to 25%<sup>1</sup>. The tribological properties of the metal-on-metal cobalt-chromium-molybdenum bearing surface<sup>2-9</sup> have contributed to the encouraging five to seven-year clinical results of both metal-on-metal hip resurfacing arthroplasty<sup>1,10-13</sup> and metal-on-metal total hip arthroplasty<sup>8,14-21</sup>.

The level of elevated serum metal ions detected in association with metal-on-metal bearing surfaces in general is not known<sup>19,22-32</sup>. We are aware of no proven long-term systemic ill effects in patients with metal-on-metal hip replacements<sup>33,34</sup>. Recently, however, isolated reports of benign but locally destructive masses associated with metal-on-metal hip resurfacing and total hip arthroplasty have appeared in the literature<sup>35-39</sup>. Pandit et al. reported on a series of twenty patients who had a symptomatic "pseudotumor," a soft-tissue mass that is associated with an implant but is neither malignant nor infectious. They estimated the incidence to be 1% at five years in patients

**Disclosure:** One or more of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of an aspect of this work. In addition, one or more of the authors, or his or her institution, has had a financial relationship, in the thirty-six months prior to submission of this work, with an entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. No author has had any other relationships, or has engaged in any other activities, that could be perceived to influence or have the potential to influence what is written in this work. The complete **Disclosures of Potential Conflicts of Interest** submitted by authors are always provided with the online version of the article.

The Journal of Bone & Joint Surgery • JBJS.org Volume 93-A • Number 23 • December 7, 2011 PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY

with hip resurfacing, but they postulated that an appreciable number of unrecognized asymptomatic pseudotumors may exist<sup>40</sup>. All patients were women, raising the possibility of a metal allergy etiology. Patients with steeply inclined acetabular cups developed symptoms within the first year, suggesting that edge loading and the release of metal debris may be important. However, the levels of serum metal ions were not known. Further study revealed higher levels of metal ions in patients with steeply inclined components and a weight-bearing arc of coverage of <10 mm (a function of acetabular component inclination, size, and design)<sup>41</sup>.

As part of a recent randomized trial<sup>42</sup> from our institution, serum cobalt (p = 0.000) and chromium (p = 0.023) ion levels were significantly higher in patients who had been managed with large-head metal-on-metal total hip arthroplasty as compared with those who had been managed with metal-on-metal hip resurfacing arthroplasty. However, there were no data on the prevalence of pseudotumor formation in the group with elevated ion levels.

The primary purpose of the present study, therefore, was to assess the prevalence of pseudotumor formation in asymptomatic patients with a metal-on-metal total hip replacement after a minimum duration of follow-up of two years. The prevalence of pseudotumor formation in asymptomatic patients with a metal-on-polyethylene total hip replacement and that in asymptomatic patients with a metal-on-metal hip resurfacing implant were evaluated at the same time point for comparison. A secondary purpose was to assess if a correlation existed between elevated serum metal ion levels and pseudotumor formation.

### **Materials and Methods**

Onsent to participate in the study was prospectively obtained from a total of seventy-five patients undergoing primary hip arthroplasty. We recruited consecutive groups of local asymptomatic patients to achieve a minimum of twenty patients in each group. Of the seventy-five patients, thirty-one underwent metal-on-metal total hip arthroplasty (M/L Taper/Durom; Zimmer, Warsaw, Indiana), twenty-four underwent metal-on-polyethylene total hip arthroplasty (M/L Taper/Trilogy; Zimmer), and twenty underwent metal-on-metal hip resurfacing arthroplasty (Durom; Zimmer). Institutional review board approval was obtained. The demographic characteristics of the study groups were similar (see Appendix). Procedures were performed by four participating surgeons (B.A.M., N.V.G., C.P.D., D.S.G.) from September 1, 2004, to June 30, 2007, during which time a total of 150 metal-on-metal total hip arthroplasties, 1091 metal-on-polyethylene total hip arthroplasties, and 400 metal-on-metal hip resurfacing arthroplasties were performed at our institution. All patients were evaluated at a minimum of two years after surgery. Patients undergoing multiple joint replacements or revision joint replacement for any reason and patients with a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)44 of <80 (indicating the presence of symptoms) were excluded from the study.

In the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups, the serum levels of metal ions were measured and an ultrasound examination of each hip was simultaneously performed to evaluate for evidence of fluid or pseudotumor formation after a minimum duration of follow-up of two years. In the metal-on-polyethylene total hip arthroplasty group, ultrasound examination of each hip was performed to look for evidence of fluid or a cystic or solid mass after a minimum duration of follow-up of two years. Pseudotumor formation was defined as a solid and/or cystic mass.

All patients completed the WOMAC<sup>43</sup>, Short Form-12 (SF-12)<sup>44</sup>, and University of California Los Angeles (UCLA)<sup>45</sup> questionnaires at the time of

admission for surgery and at the two-year follow-up. The WOMAC is a selfadministered, multidimensional index containing five dimensions for pain, two dimensions for stiffness, and seventeen dimensions for function. Each item is represented by a Likert scale<sup>46</sup> ranging from 0 (best health state) to 4 (worst health state). Each total raw score was normalized into a 0-to-100 scale, with 0 representing the worst quality of life and 100 representing the best quality of life<sup>43</sup>. The SF-12 is a subscale of the Short Form-36, with the score ranging from 0 points (worst score) to 100 points (best score)<sup>44</sup>. The UCLA activity rating has ten descriptive activity levels, ranging from wholly inactive and dependent on others (level 1) to moderate activities such as unlimited housework and shopping (level 6), regular participation in cycling (level 7), and participation in impact sports such as jogging or tennis (level 10)<sup>45</sup>.

Blood samples were obtained with use of a BD Vacutainer Safety-Lok Blood Collection Set (BD [Becton, Dickinson]; Franklin Lakes, New Jersey). The first 5 mL of blood was discarded to avoid possible contamination from the needle. A second 5 mL of blood was collected, and serum levels of cobalt and chromium were measured at the Trace Elements Laboratory–London Health Sciences Centre (London, Ontario, Canada) with use of inductively coupled plasma mass spectrometry (Thermo Fisher ELEMENT 2, High Resolution Sector Field Inductively Coupled Plasma Mass Spectrometer [HR-SF-ICP-MS]; Thermo Fisher Scientific, Waltham, Massachusetts). This is considered the gold standard for trace metal ion analysis<sup>32</sup>.

A separate blood sample was drawn at the same time for analysis of blood urea, creatinine, electrolytes, alkaline phosphatase, aspartate transaminase, and alanine transaminase.

The ultrasound examinations were all performed by two sonographers according to a standardized template with use of the ACUSON Antares Ultrasound System (Siemens Medical Solutions USA; Mountain View, California). The Siemens VFX9-4 linear transducer was used for anterior and lateral views, and the Siemens CH6-2 curvilinear transducer was used for posterior views.

The presence, size, and position of any fluid, cystic mass, or solid mass adjacent to the hip were recorded, along with any involvement of neurovascular structures. A minimum size of 10 mm in any dimension was defined as an abnormality. The volume of any fluid or mass was calculated by multiplying the maximum recorded dimensions in millimeters in each of three planes and dividing by 1000 to convert to volume in cubic centimeters (cm<sup>3</sup>).

The acetabular cup inclination was measured on a single digitally recorded anteroposterior pelvic radiograph with use of an electronic protractor. This angle and the radius of the articular surface were used to calculate the arc of the cover of the femoral head<sup>41</sup>.

#### Statistical Methods

An ordinal regression model was used to assess the predictors of pseudotumor formation<sup>47</sup>. The dependent variable was the presence of a pseudotumor. This model calculated a single odds ratio (OR) and 95% confidence interval (CI) for each covariate, independent of the rank of the response category. The assumptions of proportionality across thresholds were tested<sup>48</sup>. Summary proportional odds ratios and confidence intervals were then calculated for selected independent variables that included the type of procedure (metal-on-metal total hip arthroplasty, metal-on-polyethylene total hip arthroplasty, or metal-on-metal hip resurfacing arthroplasty), the measured serum chromium and cobalt ion levels, and various demographic parameters, including age, sex, and body mass index (BMI). In the proportional odds model for each covariate, outputs included an estimate of the regression coefficient, its standard error, Wald chi-squared statistic, p value, and the corresponding odds ratio and confidence limits.

Additionally, the Pearson correlation coefficient was calculated to test for a correlation between serum chromium or cobalt ions levels and pseudotumor volume. The Pearson correlation coefficient was also used to test for a correlation between cup inclination or arc of cover<sup>41</sup> and serum chromium or cobalt ions levels (all continuous variables). The Spearman rank correlation coefficient was also calculated to test for a correlation between cup inclination or arc of cover<sup>41</sup> and serum chromium or arc of cover<sup>41</sup> and pseudotumor formation. The Kruskal-Wallis test was used to test for a significant difference between the median serum metal ion levels in

# 2166

The Journal of Bone & Joint Surgery · JBJS.org Volume 93-A · Number 23 · December 7, 2011 PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY

	Metal-on-Metal Total Hip Arthroplasty	Metal-on-Polyethylene Total Hip Arthroplasty	Metal-on-Metal Hip Resurfacing Arthroplasty
NOMAC (points)			
Global	96.4 $\pm$ 5.6 (80 to 100)	96.2 $\pm$ 5.3 (81 to 100)	95.2 $\pm$ 5.7 (83 to 100)
Pain	95.7 $\pm$ 6.9 (75 to 100)	96.5 $\pm$ 7.4 (65 to 100)	97.5 $\pm$ 6.6 (75 to 100)
Function	96.6 $\pm$ 5.8 (78 to 100)	96.3 $\pm$ 5.7 (78 to 100)	95.4 $\pm$ 5.3 (85 to 100)
SF-12 (mental component) (points)	53.8 $\pm$ 9.4 (29 to 62)	$55.8 \pm 4.6$ (43 to 63)	54.9 $\pm$ 6.1 (37 to 62.8)
UCLA activity level (points)	$7.5 \pm 1.7$ (4 to 10)	$6.3 \pm 1.5$ (4 to 10)	$8.4 \pm 1.6$ (5 to 10)

\*The values are given as the mean and the standard deviation, with the range in parentheses. †WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index, SF-12 = Short Form-12, and UCLA = University of California Los Angeles.

	Metal-on-Metal Total Hip Arthroplasty ( $N = 31$ )	Metal-on-Polyethylene Total Hip Arthroplasty ( $N = 24$ )	Metal-on-Metal Hip Resurfacing Arthroplasty (N= 20)
Solid mass			
No. of patients	7 (23%)	0	3 (15%)
Volume† (cm <sup>3</sup> )	96.1 (8 to 437)	_	58.7 (24 to 119)
Cystic mass			
No. of patients	3 (10%)	1 (4%)	2 (10%)
Volume† (cm <sup>3</sup> )	73.5 (14 to 176)	9.8	16.0 (6 to 26))
Isolated fluid collection			
No. of patients	3 (10%)	2 (8%)	1 (5%)
Volume† (cm <sup>3</sup> )	35.2 (10 to 70)	2.9 (1 to 5)	8.4

\*The difference in the prevalence of pseudotumor formation between the metal-on-metal total hip arthroplasty and metal-on-polyethylene total hip arthroplasty groups was significant (p = 0.015). There was no significant difference in pseudotumor formation between the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups (p = 0.755) or between the metal-on-polyethylene total hip arthroplasty and hip resurfacing arthroplasty groups (p = 0.075). The values are given as the mean, with the range in parentheses.

	Metal-on-Metal Total Hip Arthroplasty (N = 31)	Metal-on-Polyethylene Total Hip Arthroplasty (N = 24)	Metal-on-Metal Hip Resurfacing Arthroplasty (N = 20)
Chromium ( $\mu g/L$ )			
Normal*	0.099 to 0.198		_
Median	2.82	_	1.08
Standard deviation	9.12		34.28
Range	0.66 to 50.47	_	0.45 to 142.46
Cobalt (µg/L)			
Normal*	0.030 to 0.400		
Median	4.50		0.83
Standard deviation	10.46	_	47.21
Range	0.54 to 58.78	_	0.39 to 195.61

\*Normal values for anyone undergoing serum metal ion testing, regardless of whether they have a metal implant or not. Normal values are determined by the Trace Elements Laboratory–London Health Sciences Centre.

THE JOURNAL OF BONE & JOINT SURGERY · JBJS.ORG VOLUME 93-A · NUMBER 23 · DECEMBER 7, 2011 PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY

	Metal-on-Metal Total Hip Arthroplasty (N = $31$ )	Metal-on-Polyethylene Total Hip Arthroplasty (N = $24$ )	Metal-on-Metal Hip Resurfacing Arthroplasty ( $N = 20$ )
Cup inclination* (deg)	41.6 $\pm$ 5.0 (35 to 52)	$42.5 \pm 6.3$ (27 to 58)	$42.9 \pm 5.7$ (33 to 58)
Arc of cover* (mm)	16.8 ± 2.0 (13 to 21)	_	17.0 ± 2.6 (11 to 21)

the groups of patients with and without pseudotumor formation. Finally, the rate of pseudotumor formation was compared between the groups (that is, metal-on-metal total hip arthroplasty compared with hip resurfacing arthroplasty, metal-on-metal total hip arthroplasty compared with metal-on-polyethylene total hip arthroplasty, and hip resurfacing arthroplasty compared with metal-onpolyethylene total hip arthroplasty) with use of the Fisher exact test (given the small number of patients in each group), and the p value was multiplied to adjust for three comparisons.

# Source of Funding

This study was funded by a grant from the University of British Columbia Orthopaedics Research Excellence Fund, with use of funds from Johnson & Johnson (Markham, Ontario, Canada). The funding source played no role in the investigation.

# Results

The demographic details for each group are summarized in the Appendix, and the clinical outcome scores are displayed in Table I. A WOMAC score ≥80 (indicating an asymptomatic patient) was one of the main criteria for entry into this study; therefore, the outcome scores in each group were good. In the metal-on-metal total hip arthroplasty group, seven patients (23%) (two men and five women) had a solid mass with mean volume of 96.1 cm<sup>3</sup> (range, 8 to 437 cm<sup>3</sup>) and three patients (10%) (one man and two women) had a cystic mass with a mean volume of 73.5 cm<sup>3</sup> (range, 14 to 176 cm<sup>3</sup>) on ultrasound examination (Figs. 1 and 2). Two of the seven patients who had a

solid mass had an associated fluid collection, and another three patients (10%) had an isolated fluid collection with a mean volume of 35.2 cm<sup>3</sup> (range, 10 to 70 cm<sup>3</sup>) (Table II).

In the metal-on-polyethylene total hip arthroplasty group, no patient had a solid mass and one patient (4%) (a woman) had a cystic mass that measured 9.8 cm<sup>3</sup> on ultrasound examination. Additionally, two patients (8%) had an isolated fluid collection with a mean volume of 2.9  $\text{cm}^3$  (range, 1 to 5  $\text{cm}^3$ ) (Table II).


In the hip resurfacing arthroplasty group, three patients (15%) (one man and two women) had a solid mass with a mean volume of 58.7 cm<sup>3</sup> (range, 24 to 119 cm<sup>3</sup>) and two patients (10%) (one man and one woman) had a cystic mass with a mean volume of 16.0 cm3 (range, 6 to 26 cm3) on ultrasound examination. One patient (5%) had an isolated fluid collection with a volume of  $8.4 \text{ cm}^3$  (Table II).

Serum chromium and cobalt ion levels in the metal-onmetal total hip arthroplasty group were a mean of fourteen times (range, five to 255 times) and eleven times (range, two to 147 times) the upper limit of normal (0.198 and 0.400 part per billion  $[\mu g/L]$ ) for chromium and cobalt, respectively. In the hip resurfacing arthroplasty group, chromium and cobalt ion levels were a mean of five times (range, two to 720 times) and two times (range, one to 489 times) the upper limit of normal (Table III). These data are represented graphically in Figs. 3 and 4, without the two excluded outliers (one patient in the large-


LT HIP ANT LONG LT POSTERIOR LONG Fig. 2

Fig. 1

Fig. 1 Ultrasound image showing a solid mass with a volume of 437 cm<sup>3</sup> in an asymptomatic woman with a metal-on-metal total hip replacement. Fig. 2 Ultrasound image showing a cystic mass with a volume of 176 cm<sup>3</sup> in an asymptomatic woman with a metal-on-metal total hip replacement.



Prevalence of Pseudotumor in Asymptomatic Patients After Metal-on-Metal Hip Arthroplasty



**Fig. 3** "Trimmed" box plot graph showing serum chromium ion levels ( $\mu$ g/L) after a minimum of two years of follow-up. THA = total hip arthroplasty and HRA = hip resurfacing arthroplasty. **Fig. 4** "Trimmed" box plot graph showing serum cobalt ion levels ( $\mu$ g/L) after a minimum of two years of follow-up. THA = total hip arthroplasty and HRA = hip resurfacing arthroplasty.

Fig. 4

head metal-on-metal total hip arthroplasty group and one in the resurfacing group). An excluded outlier was defined as a patient with a serum metal ion level that was several times greater than the second-largest value in our results. In our study, excluded outliers had an ion level of  $>50 \mu g/L$ .

Only one cup in the metal-on-metal hip resurfacing arthroplasty group, with an inclination angle of 58°, was considered to have a steep inclination angle  $(>55^{\circ})^{41}$ , and it was not associated with an ultrasound abnormality (Fig. 5-A). The resulting arc of cover was calculated as 11 mm on the basis of the radiograph. All other angles of cup inclination in the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups measured  $<55^{\circ}$  (Fig. 5-B), with corresponding arcs of cover >10 mm (Table IV)<sup>41</sup>.

# 2168

THE JOURNAL OF BONE & JOINT SURGERY · JBJS.ORG VOLUME 93-A · NUMBER 23 · DECEMBER 7, 2011 PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY



**Fig. 5-A** Anteroposterior pelvic radiograph for a patient in the metal-on-metal hip resurfacing arthroplasty group who did not have a pseudotumor abnormality on ultrasound. The cup inclination measured 58°. **Fig. 5-B** Anteroposterior pelvic radiograph for a patient in the metal-on-metal total hip arthroplasty group who did not have an ultrasound abnormality. The cup inclination measured 35°.

None of the sixteen covariates that were entered into the ordinal regression model (including serum chromium and cobalt ion levels and various demographic parameters and patient characteristics such as age, sex, and BMI) predicted pseudotumor formation.

There was no significant correlation between serum metal (chromium or cobalt) ion level and pseudotumor volume. There was no significant difference between patients with and without pseudotumor formation in terms of the median serum chromium and cobalt ion levels (p = 0.08 and 0.07, respectively). Patients with a detectable abnormality on ultrasound examination had higher median serum metal ion levels than those who did not.

Furthermore, the difference in the prevalence of pseudotumor formation between the metal-on-metal total hip arthroplasty and metal-on-polyethylene total hip arthroplasty groups was significant (p = 0.015) and remained so even after adjusting for three comparisons (p = 0.046) (that is, metal-onmetal total hip arthroplasty compared with hip resurfacing arthroplasty, metal-on-metal total hip arthroplasty compared with metal-on-polyethylene total hip arthroplasty, and hip resurfacing arthroplasty compared with metal-on-polyethylene total hip arthroplasty). There was no significant difference in pseudotumor formation between the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups (p =0.755) or between the hip resurfacing arthroplasty and metalon-polyethylene total hip arthroplasty groups (p =0.077) (Table II).

Pseudotumor formation did not correlate with either acetabular cup inclination or arc of cover in either the metalon-metal total hip arthroplasty group or the hip resurfacing arthroplasty group. The arc of cover in the metal-on-metal total hip arthroplasty group significantly correlated with the serum chromium ion level (p = 0.01) but did not significantly correlate with the serum cobalt ion level (p = 0.078). With the numbers available, the acetabular cup inclination in the hip resurfacing arthroplasty group did not significantly correlate with either serum chromium or cobalt ion levels (p = 0.072 and p = 0.076, respectively).

## Discussion

The prevalence of pseudotumor formation in a group of asymptomatic patients with a metal-on-metal implant has not previously been described, to our knowledge<sup>35-38</sup>. A previous study showed that the M/L Taper/Durom (Zimmer) total hip system produced significantly increased serum metal ion levels of chromium (p = 0.001 and cobalt (p = 0.001)<sup>42</sup>. The present study confirmed very high serum metal ion levels in this group of asymptomatic patients with a metal-on-metal-bearing surface. The serum levels of metal ions in the large-head metal-on-metal total hip arthroplasty group were considerably higher than those in the hip resurfacing arthroplasty group (Figs. 3 and 4).

In the metal-on-metal total hip arthroplasty group, ten patients (32%) had a solid (seven) or cystic (three) mass, with another three patients (10%) having an isolated fluid collection, resulting in an overall abnormality rate of 42% (thirteen of thirty-one). In the hip resurfacing arthroplasty group, five patients (25%) had a solid (three) or cystic (two) mass, with another patient (5%) having an isolated fluid collection, resulting in an overall abnormality rate of 30% (six of twenty). The mean volumes of the solid, cystic, and fluid abnormalities were greater in the metal-on-metal total hip arthroplasty group (Table II). To reiterate, all of the patients in this study were asymptomatic, with a WOMAC score of  $\geq$ 80 at the time of assessment; the higher UCLA scores in the metal-on-metal total hip arthroplasty and hip resurfacing arthroplasty groups were likely secondary to bias in the original selection of the implant (Table I).

Despite the relatively small number of patients assessed, pseudotumor formation was significantly more prevalent in the

The Journal of Bone & Joint Surgery · JBJS.org Volume 93-A · Number 23 · December 7, 2011 PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY

metal-on-metal total hip arthroplasty group compared with the metal-on-polyethylene total hip arthroplasty group (p = 0.015).

Given the numbers available in the study, we did not find a significant correlation between serum metal ion levels and the size of the pseudotumor abnormality. However, the median serum metal ion level was greater (although not significantly so) in the patients with pseudotumor formation than it was in those without pseudotumor formation. Although there may be other factors involved in the formation of a solid or cystic pseudotumor abnormality, it appeared clinically that metal ions likely played a central role. However, it might be postulated that metal ion levels in the blood serum are only a partial indication of events within the hip joint and are themselves subject to many variable influencing factors<sup>49-52</sup>.

Similar reasoning might also explain why we did not find a correlation between pseudotumor formation and cup inclination or between pseudotumor formation and arc of cover in either the metal-on-metal total hip arthroplasty group or the hip resurfacing arthroplasty group. However, cup inclination angles in this study were not classified as steep, that is, >55° of inclination<sup>41</sup>. Only one patient had a cup angle of >55°. The present study demonstrated similar trends to those found in previous studies in terms of the relationship between acetabular cup inclination<sup>26,41,52</sup> and arc of cover<sup>41</sup> and the serum level of the metal ions measured. However, serum metal ion levels did not correlate with pseudotumor formation. Studying radiographs also did not predict which patients were at risk for pseudotumor abnormality.

The results of the present study indicated that patients with metal-on-metal hip replacements, known to result in high ion levels, had high rates of pseudotumor formation. In this study, the rate ranged from 30% to 40%, depending on the type of hip arthroplasty. The important clinical question not answered in the present study was what treatment recommendations to offer asymptomatic patients with metal-on-metal implants and an associated ultrasound abnormality consistent with pseudotumor formation. The outcome of revision surgery for pseudotumors is poor in symptomatic patients<sup>53</sup>. Therefore, we recommend high-resolution ultrasound surveillance for all asymptomatic patients with metal-on-metal implants known to result in high serum metal ion levels. Once a metal-on-metal implant is known to be associated with high serum metal ion levels, the measurement of ion levels does not helpfully contribute to continued surveillance. Patients with positive findings, especially those with a large-volume pseudotumor and those who develop symptoms with a pseudotumor, require further investigation and should be considered to be candidates for early revision arthroplasty.

#### Appendix

A table showing the demographic data for the study population is available with the online version of this article as a data supplement at jbjs.org.

Note: The authors thank Daphné Savoy, Lorna Ottley, and Julie Szendrey for their assistance in the preparation of this article and Eric Sayre, PhD, for his assistance with the statistical analysis.

Daniel H. Williams, MBBCh, MSc Nelson V. Greidanus, MD, MPH Bassam A. Masri, MD Clive P. Duncan, MD, MSc Donald S. Garbuz, MD, MHSc Division of Lower Limb Reconstruction and Oncology, Department of Orthopaedics, University of British Columbia, Room 3114, 910 West 10th Avenue, Vancouver, BC V5Z 4E3, Canada. E-mail address for D.S. Garbuz: garbuz@shaw.ca

#### References

**1.** Amstutz HC, Beaulé PE, Dorey FJ, Le Duff MJ, Campbell PA, Gruen TA. Metal-onmetal hybrid surface arthroplasty: two to six-year follow-up study. J Bone Joint Surg Am. 2004;86:28-39.

**10.** Back DL, Dalziel R, Young D, Shimmin A. Early results of primary Birmingham hip resurfacings. An independent prospective study of the first 230 hips. J Bone Joint Surg Br. 2005;87:324-9.

 Daniel J, Pynsent PB, McMinn DJ. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis. J Bone Joint Surg Br. 2004;86:177-84.
Treacy RB, McBryde CW, Pynsent PB. Birmingham hip resurfacing arthroplasty. A minimum follow-up of five years. J Bone Joint Surg Br. 2005;87:167-70.

**13.** Steffen RT, Pandit HP, Palan J, Beard DJ, Gundle R, McLardy-Smith P, Murray DW, Gill HS. The five-year results of the Birmingham Hip Resurfacing arthroplasty: an independent series. J Bone Joint Surg Br. 2008;90:436-41.

 Long WT, Dorr LD, Gendelman V. An American experience with metal-on-metal total hip arthroplasties: a 7-year follow-up study. J Arthroplasty. 2004;19(8 Suppl 3):29-34.
Delaunay CP. Metal-on-metal bearings in cementless primary total hip arthroplasty. J Arthroplasty. 2004;19(8 Suppl 3):35-40.

**16.** Dorr LD, Wan Z, Longjohn DB, Dubois B, Murken R. Total hip arthroplasty with use of the Metasul metal-on-metal articulation. Four to seven-year results. J Bone Joint Surg Am. 2000;82:789-98.

**17.** Dumbleton JH, Manley MT. Metal-on-Metal total hip replacement: what does the literature say? J Arthroplasty. 2005;20:174-88.

**18.** Eswaramoorthy V, Moonot P, Kalairajah Y, Biant LC, Field RE. The Metasul metal-on-metal articulation in primary total hip replacement: clinical and radiological results at ten years. J Bone Joint Surg Br. 2008;90:1278-83.

**19.** Grübl A, Marker M, Brodner W, Giurea A, Heinze G, Meisinger V, Zehetgruber H, Kotz R. Long-term follow-up of metal-on-metal total hip replacement. J Orthop Res. 2007;25:841-8.

**20.** Sharma S, Vassan U, Bhamra MS. Metal-on-metal total hip joint replacement: a minimum follow-up of five years. Hip Int. 2007;17:70-7.

**21.** Wagner M, Wagner H. Medium-term results of a modern metal-on-metal system in total hip replacement. Clin Orthop Relat Res. 2000;379:123-33.

<sup>2.</sup> Amstutz HC, Campbell P, McKellop H, Schmalzreid TP, Gillespie WJ, Howie D, Jacobs J, Medley J, Merritt K. Metal on metal total hip replacement workshop consensus document. Clin Orthop Relat Res. 1996;(329 Suppl):S297-S303.

Chan FW, Bobyn JD, Medley JB, Krygier JJ, Yue S, Tanzer M. Engineering issues and wear performance of metal on metal hip implants. Clin Orthop Relat Res. 1996; 333:96-107.

<sup>4.</sup> Schmidt M, Weber H, Schön R. Cobalt chromium molybdenum metal combination for modular hip prostheses. Clin Orthop Relat Res. 1996:(329 Suppl):S35-47.

Sieber HP, Rieker CB, Kottig P. Analysis of 118 second generation metal-onmetal retrieved hip implants. J Bone Joint Surg Br. 1999;81:46-50.

Rieker CB, Schön R, Köttig P. Development and validation of a second-generation metal-on-metal bearing: laboratory studies and analysis of retrievals. J Arthroplasty. 2004;19(8 Suppl 3):5-11.

Chan FW, Bobyn JD, Medley JB, Krygier JJ, Tanzer M. The Otto Aufranc Award. Wear and lubrication of metal-on-metal hip implants. Clin Orthop Relat Res. 1999;369:10-24.
Jacobsson SA, Djerf K, Wahlström O. Twenty-year results of McKee-Farrar versus Charnley prosthesis. Clin Orthop Relat Res. 1996;(329 Suppl)S60-8.

**<sup>9.</sup>** McKellop H, Park SH, Chiesa R, Doorn P, Lu B, Normand P, Grigoris P, Amstutz H. In vivo wear of three types of metal on metal hip prostheses during two decades of use. Clin Orthop Relat Res. 1996;(329 Suppl):S128-40.

THE JOURNAL OF BONE & JOINT SURGERY • JBJS.ORG VOLUME 93-A • NUMBER 23 • DECEMBER 7, 2011

**22.** Antoniou J, Zukor DJ, Mwale F, Minarik W, Petit A, Huk OL. Metal ion levels in the blood of patients after hip resurfacing: a comparison between twenty-eight and thirty-six-millimeter-head metal-on-metal prostheses. J Bone Joint Surg Am. 2008;90 Suppl 3:142-8.

23. Daniel J, Ziaee H, Pradhan C, McMinn DJ. Systemic metal exposure in large- and small-diameter metal-on-metal total hip replacements. Orthopedics. 2008;31(12 Suppl 2).

24. Dobbs HS, Minski MJ. Metal ion release after total hip replacement. Biomaterials. 1980;1:193-8.

25. Grübl A, Weissinger M, Brodner W, Gleiss A, Giurea A, Gruber M, Pöll G,

Meisinger V, Gottsauner-Wolf F, Kotz R. Serum aluminium and cobalt levels after ceramic-on-ceramic and metal-on-metal total hip replacement. J Bone Joint Surg Br. 2006;88:1003-5.

**26.** Langton DJ, Jameson SS, Joyce TJ, Webb J, Nargol AV. The effect of component size and orientation on the concentrations of metal ions after resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2008;90:1143-51.

**27.** Sauvé P, Mountney J, Khan T, De Beer J, Higgins B, Grover M. Metal ion levels after metal-on-metal Ring total hip replacement: a 30-year follow-up study. J Bone Joint Surg Br. 2007;89:586-90.

**28.** Savarino L, Greco M, Cenni E, Cavasinni L, Rotini R, Baldini N, Giunti A. Differences in ion release after ceramic-on-ceramic and metal-on-metal total hip replacement. Medium-term follow-up. J Bone Joint Surg Br. 2006;88:472-6.

**29.** Vendittoli PA, Mottard S, Roy AG, Dupont C, Lavigne M. Chromium and cobalt ion release following the Durom high carbon content, forged metal-on-metal surface replacement of the hip. J Bone Joint Surg Br. 2007;89:441-8.

**30.** Allan DG, Trammell R, Dyrstad B, Barnhart B, Milbrandt JC. Serum cobalt and chromium elevations following hip resurfacing with the Cormet 2000 device. J Surg Orthop Adv. 2007;16:12-8.

**31.** Brodner W, Bitzan P, Meisinger V, Kaider A, Gottsauner-Wolf F, Kotz R. Serum cobalt levels after metal-on-metal total hip arthroplasty. J Bone Joint Surg Am. 2003;85:2168-73.

**32.** MacDonald SJ, McCalden RW, Chess DG, Bourne RB, Rorabeck CH, Cleland D, Leung F. Metal-on-metal versus polyethylene in hip arthroplasty: a randomized clinical trial. Clin Orthop Relat Res. 2003;406:282-96.

**33.** Case CP, Langkamer VG, James C, Palmer MR, Kemp AJ, Heap PF, Solomon L. Widespread dissemination of metal debris from implants. J Bone Joint Surg Br. 1994;76:701-12.

**34.** Visuri TI, Pukkala E, Pulkkinen P, Paavolainen P. Cancer incidence and causes of death among total hip replacement patients: a review based on Nordic cohorts with a special emphasis on metal-on-metal bearings. Proc Inst Mech Eng H. 2006;220: 399-407.

**35.** Pandit H, Vlychou M, Whitwell D, Crook D, Luqmani R, Ostlere S, Murray DW, Athanasou NA. Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthoplasties: evidence for a type IV immune response. Virchows Arc. 2008;453: 529-34.

**36.** Boardman DR, Middleton FR, Kavanagh TG. A benign psoas mass following metal-on-metal resurfacing of the hip. J Bone Joint Surg Br. 2006;88:402-4.

PREVALENCE OF PSEUDOTUMOR IN ASYMPTOMATIC PATIENTS AFTER METAL-ON-METAL HIP ARTHROPLASTY

**37.** Gruber FW, Böck A, Trattnig S, Lintner F, Ritschl P. Cystic lesion of the groin due to metallosis: a rare long-term complication of metal-on-metal total hip arthroplasty. J Arthroplasty. 2007;22:923-7.

 Willert HG, Buchhom GH, Fayyazi A, Flury R, Windler M, Köster G, Lohmann CH. Metal-on-metal bearings and hypersensitivity in patients with artificial hip joints. A clinical and histomorphological study. J Bone Joint Surg Am. 2005;87:28-36.
Campbell P, Shimmin A, Walter L, Solomon M. Metal sensitivity as a cause of groin pain in metal-on-metal hip resurfacing. J Arthroplasty. 2008;23:1080-5.
Andit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Gibbons CL,

**40.** Pandit H, Glyn-Jones S, McLardy-Smith P, Gundle R, Whitwell D, Globons CL, Ostlere S, Athanasou N, Gill HS, Murray DW. Pseudotumours associated with metalon-metal hip resurfacings. J Bone Joint Surg Br. 2008;90:847-51.

**41.** De Haan R, Pattyn C, Gill HS, Murray DW, Campbell PA, De Smet K. Correlation between inclination of the acetabular component and metal ion levels in metal-on-metal hip resurfacing replacement. J Bone Joint Surg Br. 2008;90:1291-7.

**42.** Garbuz DS, Tanzer M, Greidanus NV, Masri BA, Duncan CP. The John Charnley Award: metal-on-metal hip resurfacing versus large-diameter head metal-on-metal total hip arthroplasty: a randomized clinical trial. Clin Orthop Relat Res. 2010; 468:318-25.

**43.** Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833-40.

**44.** Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83.

**45.** Amstutz HC, Thomas BJ, Jinnah R, Kim W, Grogan T, Yale C. Treatment of primary osteoarthritis of the hip. A comparison of total joint and surface replacement arthroplasty. J Bone Joint Surg Am. 1984;66:228-41.

**46.** Likert R. A technique for the measurement of attitudes. Arch Psych. 1932;140:1-55.

**47.** Scott SC, Goldberg MS, Mayo NE. Statistical assessment of ordinal outcomes in comparative studies. J Clin Epidemiol. 1997;50:45-55.

**48.** Cleveland WS. DSGE. Regression by local fitting. J Econometrics. 1988;37: 87-114.

**49.** Massè A, Bosetti M, Buratti C, Visentin O, Bergadano D, Cannas M. Ion release and chromosomal damage from total hip prostheses with metal-on-metal articulation. J Biomed Mater Res B Appl Biomater. 2003;67:750-7.

**50.** Merritt K, Brown SA. Distribution of cobalt chromium wear and corrosion products and biologic reactions. Clin Orthop Relat Res. 1996;(329 Suppl):S233-43.

**51.** De Haan R, Campbell P, Reid S, Skipor AK, De Smet K. Metal ion levels in a triathlete with a metal-on-metal resurfacing arthroplasty of the hip. J Bone Joint Surg Br. 2007;89:538-41.

**52.** Khan M, Kuiper JH, Richardson JB. The exercise-related rise in plasma cobalt levels after metal-on-metal hip resurfacing arthroplasty. J Bone Joint Surg Br. 2008;90:1152-7.

**53.** Grammatopolous G, Pandit H, Kwon YM, Gundle R, McLardy-Smith P, Beard DJ, Murray DW, Gill HS. Hip resurfacings revised for inflammatory pseudotumour have a poor outcome. J Bone Joint Surg Br. 2009;91:1019-24.